ALX Oncology
alxoncology.com
Actively hiring
Science & Engineering
Biotechnology
Health Care
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
News
ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer
Achieved 40.3% ORR with evorpacept plus trastuzumab, ramucirumab and paclitaxel versus 26.6% for control, with response rates increasing to 63.6% ...
Read more
Report
Alx Oncology Holdings Inc. Announces Nature Medicine Publication of Aspen-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept ...
Read more
Report
Alx Oncology outlines interim ASPEN-09 data from 80 patients by mid-2027 as CD47-high cohort shows 22-month median PFS
Read more
Report
Daily News
The Los Angeles Daily News is the local news source for Los Angeles and the San Fernando Valley region, providing breaking news, sports, business, entertainment, things to do, opinion, photos, videos and more from L.A.
Read more
Report
ALX Oncology Reports Promising Phase 1 Results for Evorpacept in Combination with Rituximab and Lenalidomide in B-cell Non-Hodgkin Lymphoma at AACR 2025
ALX Oncology reports promising Phase 1 results for evorpacept combined with R2 in treating relapsed B-NHL at AACR 2025.
Read more
Report
ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium
SOUTH SAN FRANCISCO, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (
Read more
Report
ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024
Poster presentation will highlight new data from clinical trial evaluating evorpacept, a highly differentiated investigational CD47 blocker, in combination with zanidatamab, an investigational dual HER2-targeted bispecific antibody, in patients with advan
Read more
Report
ALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer
--ALX Oncology Holdings Inc.,, an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced the initiation of a Phase 2 investigator-sponsored trial of neoadjuvant radiation and evorpacept, a next-generati
Read more
Report